U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07377032) titled 'TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders' on Jan. 19.
Brief Summary: The goal of this clinical study is to find out whether L-serine dietary supplementation helps improve overall clinical functioning in children and young adults (2-30 years) with GRIN-related neurodevelopmental disorders (GRIN-NDD) caused by loss-of-function (LoF) variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D. It will also assess the safety and tolerability of L-serine.
The main questions it aims to answer are:
Does L-serine improve overall clinical status, measured mainly by the Clinical Global Impression-Severity (...